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ABSTRACT 
Linezolid is a valuable treatment option for central nervous system (CNS) infections 
caused by multidrug-resistant Gram-positive micro-organisms. Data regarding its 
penetration into the CNS have shown wide variability. The aim of this study was to 
describe the population pharmacokinetics of linezolid in plasma and cerebrospinal 
fluid (CSF) in critically ill patients with external CSF drainage and proven or 
suspected CNS infections. This was an observational pharmacokinetic (PK) study in 
11 critically ill patients with proven or suspected CNS infection receiving linezolid. 
Serial blood and CSF samples were taken and were subject to population PK 
analysis. The median (interquartile range) of AUC0–12h was 47.6 (17.9–58.6) mgh/L 
in plasma and 21.1 (18.8–30.4) mgh/L in CSF, with a median CSF/plasma ratio of 
0.77. At pre-dose at steady state, a strong positive correlation was observed 
between linezolid concentrations in CSF and plasma (Spearman’s rho = 0.758; P = 
0.011). For a minimum inhibitory concentration (MIC) of 2 mg/L, the median AUC0–
24h/MIC values in plasma and CSF were <80 in all patients. A three-compartment 
linear model was found to be most appropriate. The mean value for linezolid 
clearance was 16.6 L/h and mean volume of distribution was 101.3 L. No covariate 
relationships could be supported on any of the parameters. Linezolid demonstrated 
good penetration into the CNS but high interindividual PK variability. Administration 
of higher than standard doses of linezolid and therapeutic drug monitoring should 
therefore be considered as options to optimise linezolid dosing in critically ill patients 
with CNS infections. 
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1. Introduction 
Neurosurgical critically ill patients frequently require placement of an external central 
nervous system (CNS) catheter for drainage of cerebrospinal fluid (CSF) to better 
control intracranial pressure. It is estimated that 1–2% of patients admitted to an 
intensive care unit (ICU) have an intraventricular catheter in situ [1]. These devices 
are frequently manipulated to ensure optimal function and, whilst strict aseptic 
methods are targeted for use [2], CNS infections are common in these patients. The 
frequency of CNS infections resulting from neurosurgical procedures is estimated to 
be ca. 4% [3], and Gram-positive cocci, mainly Staphylococcus spp., are the most 
common causative pathogens [4]. 
 
Linezolid is considered to be a useful treatment option for CNS infections, 
particularly where mediated by resistant Gram-positive bacteria [5–7]. Linezolid has 
good antibacterial activity against these micro-organisms, including 
meticillin-resistant Staphylococcus aureus (MRSA), coagulase-negative 
staphylococci (e.g. Staphylococcus epidermidis) and vancomycin-resistant 
enterococci [8]. Over the last few years, several studies have become available that 
support the effica y and safety of linezolid in the treatment of CNS infections 
[3,9,10]. Linezolid has been reported to have a favourable pharmacokinetic (PK) 
profile, achieving high concentrations in CSF and showing a penetration ratio for the 
area under the drug concentration–time curve (AUC) for CSF to the AUC for serum 
close to 1 [11]. Some PK studies have been performed in animal models, healthy 
volunteers or non-critically ill patients [12–14]. Studies evaluating penetration of 
linezolid into the CNS in critically ill patients have shown widely variable results 
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[4,12–16]. This population can develop severe pathophysiological changes (e.g. 
hyperdynamic state, need for vasopressor drugs, augmented or impaired renal 
function) that can alter the pharmacokinetics of many antimicrobials leading to 
decreased effectiveness [17]. Such PK changes may affect antibiotic penetration into 
the CSF and cause wide interindividual variability in CSF concentrations. 
 
In human studies, the time the plasma linezolid concentration exceeds the minimum 
inhibitory concentration (T>MIC) and the ratio of AUC from time 0 to 24 h to MIC 
(AUC0–24h/MIC) have been related to bacteriological and clinical outcomes. In 
seriously ill patients, higher efficacy rates were observed when the T>MIC was 85% 
and the AUC0–24h/MIC was in the range of 80–120 [18,19]. When considering an MIC 
of 2 mg/L, optimal pharmacokinetic/pharmacodynamic (PK/PD) targets in plasma 
and CSF were achieved in the majority of the previously described experiences [12–
15]. However, using an MIC of 4 mg/L, a value for less susceptible strains [20], these 
PK/PD ratios were only achieved in two studies [12,15]. 
 
To the best of our knowledge, a population PK study of linezolid concentrations in 
plasma and CSF in critically ill patients with ventricular drains in situ is yet to be 
performed. Such an analysis could help better describe this interindividual variability 
and its implications for linezolid dosing in these patients. Given the lack of PK 
certainty of linezolid penetration into the CSF and the achievement of 
pharmacodynamic targets, the objective of this study was to describe the population 
pharmacokinetics of linezolid in plasma and CSF in critically ill patients with external 
CNS drainage and proven or suspected CNS infections. 
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2. Materials and methods 
2.1. Study design and population 
This was a prospective PK study undertaken in the 18-bed ICU of Hospital del Mar, a 
400-bed tertiary university hospital in Barcelona, Spain. All consecutive adult 
patients admitted to the ICU between January 2010 and January 2013 who received 
intravenous (i.v.) linezolid for >3 days for the treatment of a proven or suspected 
CNS infection caused by a resistant Gram-positive organism were eligible for 
inclusion. Only those patients in whom a Gram-positive micro-organism was isolated 
in a CSF culture were considered as having a proven CNS infection. All enrolled 
patients had an external CNS drainage (either intraventricular or external lumbar) 
present. All included patients received linezolid (Zyvoxid; Pfizer, Madrid, Spain) 600 
mg every 12 h as a 1-h infusion via a central venous catheter. Informed consent was 
obtained from all participating patients or their legal representatives. 
 
Various demographic, clinical and treatment data were collected, including age, sex, 
weight, height, body mass index (BMI), presence of underlying CNS disease, 
sickness severity score on admission to the ICU [described using the Acute 
Physiology and Chronic Health Evaluation (APACHE) II score], type of treatment 
with linezolid (empirical or directed), treatment duration, concomitant therapies [21], 
presence of oedema, type of external CNS drainage (ventricular or lumbar), 
glomerular filtration rate (GFR) [calculated by the Modification of Diet in Renal 
Disease (MDRD-6) equation], haematological parameters (haemoglobin and platelet 
count) at the start and end of treatment with linezolid), clinical and microbiological 
data, and crude mortality. 
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Anaemia and thrombocytopenia related to linezolid administration were defined 
according to the Common Terminology Criteria for Adverse Events (CTCAE) v.4.0. 
For patients with normal baseline values, anaemia was defined as a reduction in 
haemoglobin in the range of 8–10 g/dL or less, and thrombocytopenia was defined 
as a platelet count <75 000 cells/mm3 unexplained by any other causes. 
 
The presence of oedema was evaluated on the basis of physical examination by the 
responsible clinician. 
 
2.2. Plasma and cerebrospinal fluid sample collection 
Plasma and CSF sampling occurred after 3 days of treatment. Blood samples (4 mL) 
were collected just before initiation of the linezolid infusion (trough in plasma; Cmin,ss) 
and at 1 h (peak in plasma; Cmax,ss) in four patients and also at 3, 5, 8 and 12 h 
thereafter in seven patients. CSF samples (1 mL) were collected simultaneously with 
each blood sample. Blood and CSF samples were collected in heparinised tubes, 
immediately centrifuged (3000 u g for 10 min at 4 qC) and the plasma was stored at 
–80 qC until analysis. 
 
2.3. Bioanalysis 
Linezolid concentrations were determined using a validated high-performance liquid 
chromatography (HPLC) method. For each sample of plasma and CSF, 100 PL was 
mixed with 100 PL of methanol and was vortexed for 10 s. The mixture was then 
centrifuged for 5 min at 15 000 u g in a refrigerated laboratory centrifuge (MPW-
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260R; MPW Med. Instruments, Warsaw, Poland) and 50 PL of the supernatant was 
injected into the system for assay. 
 
The HPLC equipment was modular, including a binary pump (Waters 1525; Waters 
Corp., Milford, MA) with column heater oven, a degasser (Waters In-line degasser), 
an automatic injector (Waters 717plus Autosampler) and a UV-VIS 
spectrophotometric detector (Waters 2487). The stationary phase was a Waters 
SunFire® column (C18, 4.6 u 15.0 mm, 5 Pm) protected by a Waters SunFire® 
GuardColumn (C18, 4.6 mm u 20 mm, 5 Pm). The mobile phase consisted of a 
mixture of sodium acetate buffer (pH 3.4) and acetonitrile (80:20 v/v) delivered at an 
isocratic flux of 1.3 mL/min. The chromatogram run time was 10 min and the detector 
wavelength was set at 250 nm. 
 
The method was proven to be sensitive and specific to measure linezolid in plasma 
and CSF. The assay response was linear (coefficient of linearity >0.99) over the full 
range of concentrations assayed (0.5–30 mg/L in plasma and 0.1–20 mg/L in CSF). 
The limit of quantification was 0.5 mg/L in plasma and 0.1 mg/L in CSF. Imprecision 
values were <15% over the entire range of calibration standards, and accuracy was 
within the range of 85–115% for all concentrations. 
 
2.4. Population pharmacokinetic analysis 
The concentration–time data for linezolid in plasma and CSF were fitted using non-
linear mixed-effects modelling (NONMEM v.7.2; Globo Max LLC, Hanover, MD) [22]. 
A Digital Fortran compiler was used and the runs were executed using Wings for 
NONMEM (http://wfn.sourceforge.net). Data were analysed using the first-order 
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conditional estimation method with interaction (ADVAN6). Between-subject variability 
(BSV) was calculated using an exponential variability model and was assumed to 
follow a log-normal distribution. Residual unexplained variability was modelled using 
a combined exponential and additive random error model. Visual inspection of 
diagnostic scatter plots and the NONMEM objective function value (OFV) were used 
to evaluate goodness of fit. Statistical comparison of nested models was undertaken 
in the NONMEM program on the basis of a F2 test of the difference in OFV. A 
decrease in the OFV of 3.84 units (P < 0.05) was considered statistically significant. 
Decreases in BSV of one of the parameters of at least 10% were also accepted for 
inclusion of a more complicated model. Specifically, volume of distribution of the 
central compartment (Vc), volume of distribution of the peripheral compartment (Vp), 
volume of distribution of the CSF compartment (VCSF), intercompartmental clearance 
between plasma and tissue (Q), intercompartmental clearance between plasma and 
CSF (QCSF) and linezolid clearance (CL) were calculated using NONMEM. 
 
2.4.1. Population pharmacokinetic model diagnostics 
Visual inspection of diagnostic scatter plots and the NONMEM OFV were used to 
evaluate goodness of fit. Statistical comparison of nested models was undertaken in 
the NONMEM program using log-likelihood ratios, which are assumed to be F2 
distributed. On the basis of a F2 test of the difference in OFV, a decrease in the OFV 
of 3.84 units (P < 0.05) for one degree of freedom was considered statistically 
significant. Decreases in BSV of one of the parameters of at least 10% were also 
accepted for inclusion of a more complicated model. 
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2.4.2. Population pharmacokinetic covariate screening 
Covariate model building was performed in a stepwise fashion with forward inclusion 
and backward deletion based upon the aforementioned model selection criteria. Age, 
sex, weight, serum creatinine concentration, APACHE II score and use of 
vasopressors were evaluated as covariates. 
 
2.4.3. Population pharmacokinetic bootstrap 
A non-parametric bootstrap method (n = 1000) was used to study the uncertainty of 
the PK parameter estimates in the final model. From the bootstrap empirical 
posterior distribution, we have been able to obtain the 95% confidence interval (CI) 
for the parameters, as described previously [23]. 
 
2.5. Other pharmacokinetic calculations 
The maximum (Cmax) and minimum (Cmin) concentration in plasma and CSF for the 
dosing interval were the observed values. The AUC from 0 to 12 h (AUC0–12h) was 
calculated using the trapezoidal rule. AUC0–24h was calculated as AUC0–12h u 2. 
Penetration of linezolid into the CSF was described using the CSF/plasma ratio, 
which was calculated by dividing the CSF AUC0–12h by the plasma AUC0-12h. 
 
2.6. Assessment of pharmacodynamics and efficacy thresholds 
An AUC0–24h/MIC ratio of 80–120 was considered the optimal target for efficacy 
because this threshold has been related to higher clinical success and 
bacteriological rates [19,24]. 
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2.7. Statistical analysis 
Continuous variables were compared with the Student’s t-test or Mann–Whitney U-
test as appropriate, and dichotomous variables were compared using the F2 test or 
Fisher’s exact test. Bivariate linear correlations were studied using the Spearman’s 
rho (U) test or the Pearson test, when appropriate. For all analyses, a two-sided P-
value <0.05 was considered statistically significant. SPSS v.13.0 (SPSS Inc., 
Chicago, IL) was used throughout. GraphPad Prism v.6.0 (GraphPad Software Inc., 
La Jolla, CA) was used for linear regression calculations. Data are described as the 
mean ± standard deviation or median [interquartile range (IQR)] as appropriate. 
 
3. Results 
Eleven patients were included in the study and 46 blood samples and 45 CSF 
samples were collected. The demographic and clinical characteristics of the patients 
are detailed in Table 1. The mean patient age was 51.9 ± 10.3 years and 7 (63.6%) 
were male. The most frequent neurological disease was subarachnoid haemorrhage, 
observed in 7 (63.6%) of the patients. Ten patients (90.9%) were CSF-culture 
negative and one patient (9.1%) cultured S. epidermidis that was susceptible to 
linezolid. The mean treatment duration with linezolid was 9.5 ± 6.2 days. No patient 
had a GFR < 80 mL/min on the day of sampling. 
 
Plasma peak concentrations of linezolid ranged from 6.3 mg/L to 17.3 mg/L and 
plasma trough concentrations ranged from <0.2 mg/L to 2 mg/L. In CSF, the peak 
concentration ranged from 1.3 mg/L to 7.1 mg/L and the trough concentration from 
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<0.2 mg/L to 3.1 mg/L. The median (IQR) of AUC0–12h was 47.6 (17.9–58.6) mgh/L 
in plasma and 21.1 (18.8–30.4) mgh/L in CSF. This corresponded to a median 
CSF/plasma ratio between patients of 0.77. The steady-state plasma and CSF 
concentration–time profiles are shown in Fig. 1. Linezolid concentration profiles in 
plasma and CSF were not superimposable. The Cmax in plasma was the observed 
value at the end of the i.v. infusion, whilst in CSF it was achieved ca. 3–5 h after the 
beginning of linezolid administration. At the time of Cmin, a strong positive correlation 
was observed between linezolid concentrations in CSF and plasma (Spearman’s U = 
0.758; P = 0.011) (Fig. 2). This correlation was not observed at Cmax (Pearson’s U = –
0.266; P > 0.05). 
 
The AUC0–12h values in plasma and CSF for individual patients as well as the 
corresponding PK/PD indices related to linezolid efficacy (AUC0–24h/MIC) in plasma 
and CSF relative to different MIC values (1, 2 and 4 mg/L) are described in Table 2. 
Linezolid was well tolerated by all patients, with no adverse effects observed in any 
of the patients. 
 
3.1. Pharmacokinetic model building 
Eight patients were used to build the model as three patients did not have sufficient 
data points (more than two plasma and CSF samples) to meet the a priori model-
building criteria. The time course of linezolid in plasma and CSF was best described 
by a three-compartment linear model with combined residual error (additive error for 
the plasma and CSF predictions was fixed at 0.03 mg/L) and BSV on Vc, Vp, Q and 
CL. BSV could not be supported on VCSF or QCSF. This model included zero-order 
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input of drug into the central compartment. The mean parameter estimates from the 
final covariate model as well as the 95% CIs from all bootstrap runs are shown in 
Table 3. The goodness of fit plots are shown in Fig. 3. After screening all relevant 
biologically plausible covariates, none were found to statistically significantly improve 
the model so could not be included in the final model. 
 
4. Discussion 
To the best of our knowledge, this is the first population PK study of linezolid in 
plasma and CSF in critically ill neurological patients with proven or suspected CNS 
infection caused by Gram-positive micro-organisms. It is also the largest study of its 
type with linezolid. The results showed a moderate-to-good overall penetration of 
linezolid into the CSF, with a median AUC0–12h CSF/plasma ratio of 0.77. Despite 
this, a wide variability between patients was observed in the plasma and CSF 
concentrations and CSF/plasma ratios. This variability is most likely due to the range 
of sickness severity of the included patients and the consequent effect that the 
associated altered physiology has on linezolid disposition. These findings, which 
agree with those from previous studies that have also described large interindividual 
variability in the concentrations of linezolid in plasma [21] and CSF [12], support the 
need for therapeutic drug monitoring (TDM) of linezolid in plasma and also 
potentially in CSF to avoid treatment failures due to underexposure [21]. The strong 
positive correlation observed between the Cmin,ss of linezolid in plasma and the 
concentration in CSF suggests that plasma concentrations could be used as 
predictors of CSF concentrations if only trough concentration (as opposed to AUC0–
24h) monitoring was available. 
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Variable results have been published on whether plasma linezolid concentrations 
can be used as a surrogate of CSF concentrations. In one case study of linezolid in 
meningitis, the authors reported similar drug concentrations in plasma and CSF and 
suggested that plasma concentrations are a suitable indicator of CSF penetration 
[15]. This is unsurprising as drug penetration in meningitis should be greater than in 
patients with non-inflamed meninges. Similar to this case study, other authors also 
described positive correlations between the Cmax,ss of linezolid in plasma and in CSF 
[12]. However, other investigators have not found such correlations between in 
plasma and CSF concentrations of linezolid [16]. In our patients, although significant 
correlation between plasma and CSF concentrations was seen for trough 
concentrations, significant other correlations were not observed. The variable 
CSF/plasma AUC ratios seen in this study suggest that consistent correlations are 
generally unlikely with this drug. 
 
In this study, the linezolid concentrations in plasma and CSF were much lower than 
those reported in most other PK studies performed in critically ill patients [12–15,25]. 
The population PK model that best described the data was a three-compartment 
linear model. The mean volume of distribution of linezolid (101.3 L) estimated in this 
study was much higher than that reported in previous studies in the same patient 
group (42.8 L or 40.1 L) [13,14]. Our volume of distribution estimates are more in line 
with those from another critically ill patient PK study [26]. In contrast, the estimated 
linezolid clearance (16.6 L/h) was found to be much higher (7.3 L/h or 7.9 L/h) 
[12,13], a fact probably explained by the better apparent renal function of our 
patients compared with those included in the previous studies. The estimated 
Page 15 of 31
Ac
ce
pte
d M
an
us
cri
pt
clearance values described in this study more closely align with the estimates from a 
sepsis cohort reported by Plock et al. [27]. 
 
From a pharmacodynamic viewpoint, the plasma and CSF trough concentrations of 
linezolid did not exceed the European Committee on Antimicrobial Susceptibility 
Testing (EUCAST) breakpoints for susceptible pathogens (4 mg/L) [20] in any of the 
patients. Assuming an MIC of 1 mg/L, only four patients achieved a target AUC0–
24h/MIC of 80 in plasma and only one patient achieved this target in CSF. At higher 
MIC values (2 mg/L or 4 mg/L), none of the patients achieved the desired 
pharmacodynamic target. Consequently, in critically ill patients with CNS infections 
caused by a Gram-positive bacterium with a linezolid MIC  1mg/L, the standard 
dosing regimen of linezolid 600 mg twice daily is considered unlikely to achieve 
optimal plasma and CSF concentrations. 
 
The increased volume of distribution and clearance observed in our patients results 
from the generally lower linezolid PK exposures observed. The study by Myrianthefs 
et al. [12] in 14 critical neurosurgical patients receiving linezolid for a mixture of 
treatment and prophylaxis of CNS infections showed higher mean plasma Cmax,ss 
and Cmin,ss values of 18.6 mg/L (78% higher than our patients) and 5.6 mg/L (1120% 
higher), respectively. The mean CSF Cmax,ss and Cmin,ss values were also higher in 
the Myrianthefs et al. study at 10.8 mg/L (337% higher) and 6.1 mg/L (1220% 
higher), respectively [12]. The report from Beer et al. in five critically ill patients with 
ventriculitis caused by Staphylococcus spp. reported less discordant results, with a 
mean plasma Cmax,ss and Cmin,ss of 19.5 mg/L (88% higher) and 1.9 mg/L (380% 
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higher) [13]; the mean CSF Cmax,ss and Cmin,ss were 7.1 mg/L (222% higher) and 3.1 
mg/L (620% higher) [13]. 
 
One likely explanation for the lower exposures of linezolid observed in our patients is 
the conserved renal function of our patients. In particular, the mean calculated 
creatinine clearance (CLCr) estimates of our patients were much higher than those 
reported in the Myrianthefs et al. study (151 mL/min compared with 81 mL/min) [12]. 
A correlation between a low Cmin,ss of linezolid in plasma and increasing calculated 
CLCr has been shown previously [28]. In a recent study of 78 patients with acute 
infections, a value of calculated CLCr > 80 mL/min was identified as a risk factor for 
achieving a linezolid Cmin < 2 mg/L in plasma (odds ratio = 10; 95% CI 2.732–37.037; 
P = 0.001) [28]. However, this association was not observed in the current study, 
where linezolid levels in plasma and CSF were not correlated with patients’ renal 
function, probably due to the comparatively smaller sample size. This phenomenon 
of augmented renal clearance (ARC) and its association with increased antibiotic 
clearance and decreased concentrations has been previously shown for E-lactams 
[29]. In our patients, ARC is likely and would be caused by the pathophysiological 
response to the CNS pathology, including increased renal blood flow [30]. The 
effects of ARC on linezolid pharmacokinetics has not been previously described, 
although direct causality cannot be shown here as measured CLCr data were not 
available and neither were urine concentration data. One limitation of this study is 
the fact that CLCr of patients was estimated because the measurement is not 
routinely performed in Hospital del Mar. 
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Regarding toxicity, administration of linezolid at standard dosages was not 
associated with any haematological toxicity, although prolonged durations of therapy 
were not required in this study. 
 
In conclusion, this is the largest PK study of critically ill patients with proven or 
suspected CNS infection caused by Gram-positive micro-organisms. We found that 
linezolid showed a generally good distribution into the CSF, although wide 
interindividual variability in the plasma and CSF concentrations was observed. This 
variability is associated with suboptimal pharmacodynamic target attainment for 
pathogens with an MIC  1mg/L. 
 
To address this challenge, other different dosing strategies, such as administration of 
higher than standard dosages or administration by continuous infusion, should be 
considered to avoid treatment failures due to antibiotic underexposure. The 
alternative approach to optimise drug exposures is to apply individualised dosing in 
the form of TDM to overcome this PK variability. The feasibility of TDM of linezolid 
has previously been demonstrated by Pea et al. [21]. The strong linear correlation 
observed in this study between the trough linezolid concentrations in plasma and in 
CSF suggests that plasma concentrations can be used as a surrogate of CSF 
concentrations for TDM in similar critically ill neurosurgical patients. 
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Fig. 1. Plasma (top panel) and cerebrospinal fluid (lower panel) concentrations of 
linezolid over one dosing interval. Each individual data point is represented by a 
black circle, and the unbroken line is the median concentration value. 
 
Fig. 2. Correlation between plasma and cerebrospinal fluid (CSF) concentration of 
linezolid (LZD) at the trough time (before next dose administration) (n = 10; the 11th 
patient did not have a true trough value for both plasma and CSF and so could not 
be included). 
 
Fig. 3. Diagnostic plots for the final population pharmacokinetic model. Individual 
predicted linezolid concentrations in plasma versus observed plasma concentrations 
(R2 = 0.91) (top panel) and individual predicted linezolid concentrations in 
cerebrospinal fluid (CSF) versus observed CSF concentrations (R2 = 0.82) (lower 
panel). The linear regression line of fit is shown by the solid black line. 
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Table 1 
Patient demographics and clinical characteristics 
Pati
ent 
S
e
x 
Age 
(ye
ars) 
Bo
dy 
wei
ght 
(kg
) 
Seru
m 
creati
nine 
(Pmol
/L) 
GFR 
on 
the 
day 
of 
inclu
sion 
(mL/
min) 
a 
APA
CHE 
II 
scor
e 
CNS 
disease 
CNS 
exter
nal 
drain
age 
LZD 
dos
e/kg 
bod
y 
weig
ht 
(mg/
kg) 
Vasopr
essor 
therap
y 
Crud
e 
mort
ality 
1 F 45 90 38 148.
3 
9 Brain 
tumour 
ELD 13.3 No N 
2 M 42 90 50 164.
8 
24 SAH EVD 13.3 Yes N 
3 M 44 55 41 211.
4 b 
16 Hydroce
phalus 
ELD 21.8 No Y 
4 M 39 65 47 158.
5 
12 SAH EVD 18.5 No N 
5 F 51 80 42 113.
7 
22 Brain 
tumour 
ELD 15.0 Yes Y 
6 M 64 80 51 124.
1 
19 SAH EVD 15.0 No N 
7 F 74 60 32 148.
7 
24 SAH EVD 20.0 No N 
8 M 48 85 41 89.5 19 SAH EVD 14.1 Yes Y 
9 F 54 70 20 255.
3 
24 SAH ELD 
and 
EV
D 
17.1 Yes N 
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10 M 58 75 40 158.
7 
22 SAH EVD 16.0 Yes N 
11 M 52 95 36 205.
0 
26 Cerebell
ar 
haemor
rhage 
ELD 
and 
EV
D 
12.6 No N 
Me
dia
n 
– 51 80 41 158.
5 
22 – – 15.0 – – 
IQR – 46-
57 
71-
89 
37-46 136.
2-
184
.9 
19-
24 
– – 13.7
–
17.
8 
– – 
GFR, glomerular filtration rate; APACHE, Acute Physiology and Chronic Health 
Evaluation; CNS, central nervous system; LZD, linezolid; SAH, subarachnoid 
haemorrhage; ELD, external lumbar drain; EVD, external ventricular drain; IQR, 
interquartile range. 
a GFR calculated by the Modification of Diet in Renal Disease MDRD-6. 
b GFR was calculated by the Modification of Diet in Renal Disease MDRD-4 due to a 
lack of serum albumin concentrations. 
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Table 2 
Individual pharmacokinetic results in plasma and cerebrospinal fluid (CSF) and 
values of the AUC0–24h/MIC of linezolid in plasma and CSF calculated for different 
MICs 
Patient Plasma 
AUC0–12h 
(mgh/L) 
CSF 
AUC0–
12h 
(mgh/L) 
Ratio 
CSF 
AUC0–
12h to 
plasma 
AUC0–
12h 
Plasma AUC0-
24h/MIC ratio 
CSF AUC0-24h/MIC 
ratio 
MIC (mg/L): MIC (mg/L): 
1 2 4 1 2 4 
1 57.6 21.1 0.37 115.2 57.6 28.8 42.2 21.1 10.6
2 61.5 47.4 0.77 123.0 61.5 30.8 94.8 47.4 23.7
4 18.7 17.0 0.91 37.40 18.7 9.4 34.0 17.0 8.5 
5 59.5 28.7 0.48 119.0 59.5 29.8 57.4 28.7 14.4
6 17.1 14.2 0.83 34.2 17.1 8.6 28.4 14.2 7.1 
7 47.6 32.0 0.67 85.2 47.6 23.8 64.0 32.0 16.0
8 16.3 20.6 1.26 32.6 16.3 8.2 41.2 20.6 10.3
Median 47.6 21.1 0.77 85.2 47.6 23.8 42.2 21.1 10.6
IQR 17.9–
58.6 
18.8–
30.4 
0.58–
0.87 
35.8–
117.1 
17.9–
58.6 
9.0–
29.3
31.2–
60.7 
18.8–
30.4 
9.4–
15.2
AUC0–12h, area under the drug concentration–time curve from time 0 to 12 h; AUC0–
24h, area under the drug concentration–time curve from time 0 to 24 h (calculated as 
AUC0–12h u 2); MIC, minimum inhibitory concentration; IQR, interquartile range. 
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Table 3 
Mean parameter estimates and bootstrap mean (95% CI) estimates for the final 
covariate model 
Parameter Model mean Bootstrap 
Mean 95% CI 
Fixed effects 
CL (L/h) 16.6 16.7 11.5–23.6
Vc (L) 43.2 42.7 33.6–52.2
Vp (L) 58.0 57.7 50.7–65.9
VCSF (L) 0.11 0.11 0.11–0.11
Q (L/h) 3.1 2.5 0.9–5.5 
QCSF (L/h) 0.05 0.04 0.03–0.05
Random effects BSV (% CV) 
CL (L/h) 50.2 46.7 32.6–60.0
Vc (L) 15.3 10.8 0.1–29.1 
Vp (L) 8.2 5.1 0.2–29.1 
Q (L/h) 88.9 77.1 0.8–142.4
Random error 
Plasma RUV (% CV) 0.03 0.03 – 
CSF RUV (% CV) 29.8 27.7 14.0–38.6
Plasma RUV (S.D., mg/L) 0.03 0.03 – 
CSF RUV (S.D., mg/L) 36.6 34.8 27.0–42.5
CI, confidence interval; CL, linezolid clearance; Vc, volume of distribution of the 
central compartment; Vp, volume of distribution of the peripheral compartment; VCSF, 
volume of distribution of the CSF compartment; Q, intercompartmental clearance 
between plasma and tissue; QCSF, intercompartmental clearance of the CSF 
compartment; BSV, between-subject variability; CV, coefficient of variation; RUV, 
residual unexplained variability; S.D., standard deviation. 
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Edited Figure 1
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The Highlights section should be as follows: 
 
1. In these patients, Linezolid demonstrated good but variable 
penetration into the CNS. 
2. A 3-compartment model was used; the mean value for linezolid 
clearance was 16.6 L/h and volume of distribution 101.3L  
 
3. to ensure all patients achieve adequate CNS concentrations the use of 
higher than standard doses and TDM is necessary. 
 
I hope this meets with your satisfaction 
 
